Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Investment analysts at Jefferies Group dropped their FY2016 earnings per share estimates for shares of Ultragenyx Pharmaceutical in a report issued on Monday. Jefferies Group analyst G. Wang now forecasts that the firm will post earnings per share of ($6.32) for the year, down from their previous estimate of ($5.92). Jefferies Group has a “Buy” rating and a $109.00 price objective on the stock. Jefferies Group also issued estimates for Ultragenyx Pharmaceutical’s Q4 2016 earnings at ($1.86) EPS, FY2017 earnings at ($6.62) EPS, FY2018 earnings at ($5.13) EPS, FY2019 earnings at ($1.31) EPS and FY2020 earnings at $3.41 EPS.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported ($1.64) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.53) by $0.11. During the same quarter last year, the business earned ($1.03) earnings per share.

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Several other equities research analysts have also issued reports on the company. Canaccord Genuity reaffirmed a “buy” rating and set a $120.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Friday, July 15th. Piper Jaffray Cos. set a $82.00 target price on Ultragenyx Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, August 9th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $101.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. Robert W. Baird reaffirmed an “outperform” rating and set a $85.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Monday, July 18th. Finally, Cowen and Company reaffirmed a “buy” rating on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, August 9th. Two research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $95.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 78.72 on Thursday. The firm’s market cap is $3.10 billion. The company has a 50-day moving average price of $66.18 and a 200-day moving average price of $63.65. Ultragenyx Pharmaceutical has a 1-year low of $46.52 and a 1-year high of $117.12.

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the firm’s stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $63.02, for a total value of $1,260,400.00. Following the sale, the chief executive officer now owns 480,632 shares of the company’s stock, valued at approximately $30,289,428.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Shalini Sharp sold 12,000 shares of the firm’s stock in a transaction dated Wednesday, October 19th. The shares were sold at an average price of $61.40, for a total value of $736,800.00. Following the completion of the sale, the chief financial officer now directly owns 57,387 shares in the company, valued at approximately $3,523,561.80. The disclosure for this sale can be found here. 10.10% of the stock is owned by company insiders.

Several hedge funds have recently added to or reduced their stakes in the stock. Morgan Stanley boosted its stake in Ultragenyx Pharmaceutical by 52.9% in the third quarter. Morgan Stanley now owns 49,933 shares of the biopharmaceutical company’s stock valued at $3,541,000 after buying an additional 17,272 shares during the last quarter. Pacer Advisors Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 9.4% in the third quarter. Pacer Advisors Inc. now owns 2,237 shares of the biopharmaceutical company’s stock worth $159,000 after buying an additional 192 shares in the last quarter. Bellevue Group AG boosted its position in shares of Ultragenyx Pharmaceutical by 53.6% in the third quarter. Bellevue Group AG now owns 43,000 shares of the biopharmaceutical company’s stock worth $3,050,000 after buying an additional 15,000 shares in the last quarter. Principal Financial Group Inc. boosted its position in shares of Ultragenyx Pharmaceutical by 6.4% in the third quarter. Principal Financial Group Inc. now owns 71,164 shares of the biopharmaceutical company’s stock worth $5,048,000 after buying an additional 4,272 shares in the last quarter. Finally, Princeton Alpha Management LP boosted its position in shares of Ultragenyx Pharmaceutical by 67.4% in the third quarter. Princeton Alpha Management LP now owns 7,382 shares of the biopharmaceutical company’s stock worth $524,000 after buying an additional 2,973 shares in the last quarter. 93.14% of the stock is currently owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. The Company is engaged in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases segment.

5 Day Chart for NASDAQ:RARE

Receive News & Stock Ratings for Ultragenyx Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical Inc. and related stocks with our FREE daily email newsletter.